All of 23andMe's independent directors resigned from its board this week, a rare move that marks the latest challenge for the genetic-testing company.
The directors said they would be resigning effective immediately — arguing that, while they still believed in 23andMe's mission, their departures were for the best due to Wojcicki's concentrated voting power and a "clear" difference of opinion on the company's future.
Wojcicki later responded to the resignations in a memo to employees, published in a securities filing, saying she was "surprised and disappointed" by the directors' decision. Still, she maintained that taking 23andMe private and "outside of the short term pressures of the public markets" would be best for the company long term.
Subscribe our newsletter to stay updated
Thank you for subscribing!
Subscribe our newsletter to stay updated
Thank you for subscribing!
